In a recent NEJM paper a mRNA vaccine was discussed and its early efficacy analyzed. The vaccine is described as:
The candidate vaccine mRNA-1273 is a lipid nanoparticle–encapsulated,
nucleoside-modified messenger RNA (mRNA)–based vaccine that encodes the
SARS-CoV-2 spike (S) glycoprotein stabilized in its prefusion
conformation. The S glycoprotein mediates host cell attachment and is
required for viral entry; it is the primary vaccine target for many candidate SARS-CoV-2 vaccines.
This is a somewhat different approach to vaccines but it is more of a putative therapeutic. The results indicate:
The mRNA-1273 vaccine induced anti–SARS-CoV-2 immune responses in all
participants, and no trial-limiting safety concerns were identified.
These findings support further development of this vaccine.
These safety and immunogenicity findings support advancement of the
mRNA-1273 vaccine to later-stage clinical trials. Of the three doses
evaluated, the 100-μg dose elicits high neutralization responses and
Th1-skewed CD4 T cell responses, coupled with a reactogenicity profile
that is more favorable than that of the higher dose. A phase 2 trial of
mRNA-1273 in 600 healthy adults, evaluating doses of 50 μg and 100 μg,
is ongoing (ClinicalTrials.gov number, NCT04405076. opens in new tab). A large phase 3 efficacy trial, expected to evaluate a 100-μg dose, is anticipated to begin during the summer of 2020.
Hopefully this can work yet we are still concerned about lasting Ab responses.
Posts
